In the pharmaceutical industry, where patient safety and regulatory compliance are paramount, Certificates of Analysis (COAs) are critical. These documents verify that raw materials, intermediates, and finished products meet predefined quality and safety standards. As companies adopt automation to streamline workflows, one truth stands out: in COA automation, the most critical step is ensuring data accuracy and integrity at the point of extraction.

Why Accuracy at Extraction Matters

Pharma COAs arrive in a wide variety of formats—PDFs, scanned images, or supplier-specific templates. Each document carries crucial details: assay results, impurity levels, dissolution rates, and compliance thresholds. A single misinterpretation—for example, reading “0.02%” as “0.2%”—can cascade into flawed validations, ERP mis-entries, or incorrect regulatory filings. The consequences can be severe: compliance breaches, costly recalls, or even risks to patient health.

A 2023 Deloitte survey revealed that up to 40% of pharma firms report compliance gaps directly tied to poor data capture in quality documentation. This proves that even the most advanced validation or integration systems cannot correct errors created at the extraction stage.

Regulatory and Client Expectations

Global regulators such as the FDA (21 CFR Part 11) and EMA place strict emphasis on data integrity, requiring pharmaceutical firms to prove that their records are authentic, consistent, and accurate. Any missteps in COA accuracy can result in FDA warning letters, production halts, or import bans.

Beyond regulators, clients demand error-free data as well. In tightly interlinked supply chains, a single inaccurate COA entry can delay drug release or shake trust. According to PwC, nearly 60% of pharma executives rank error-free quality data as the top factor in sustaining supplier-client relationships.

A Real-World Example: Novartis

Novartis, one of the world’s largest pharmaceutical companies, undertook a digital quality transformation initiative to strengthen its global supply chain. By implementing AI-driven document processing for COAs, Novartis was able to reduce manual quality checks by 65% and cut down review cycle times significantly. More importantly, automated extraction ensured accurate capture of assay and impurity data across thousands of supplier COAs. This allowed faster batch release, improved regulatory audit readiness, and created a single source of truth across their ERP and LIMS platforms.

Their experience illustrates how building accuracy at the point of extraction forms the foundation for efficiency, compliance, and trust. Without that foundation, downstream automation risks collapsing like a skyscraper built on weak ground.

The Payoff: Speed, Savings, and Safety

Accurate COA automation delivers multiple benefits. It reduces manual verification time by 50–70%, freeing skilled quality teams for higher-value work. It also minimizes human error, lowering the likelihood of recalls that, according to FDA estimates, cost $20 million to $100 million per incident. McKinsey further notes that pharma quality teams spend 25–30% of their time on manual document checks—time that automation can reclaim.

Ultimately, the integrity of COA data at extraction determines whether automation is a compliance liability or a competitive advantage. For pharmaceutical companies, the future of automation is not just about digitization—it is about building a foundation of trust, accuracy, and reliability from the very first data point.

Manufacturers across metals, chemicals, and plastics share one truth: documentation is as critical as the material itself. Two of the most important documents—Mill Test Reports (MTRs) and Certificates of Analysis (COAs)—may sound similar, but they differ in purpose, structure, and compliance implications.

Star Software takes a domain-specific approach, recognizing that a one-size-fits-all automation model won’t work. Here’s how the processes diverge—and why that matters for manufacturers in steel, aluminum, pharmaceuticals, and plastics.

MTR vs. COA: The Key Difference

• MTR (Mill Test Report): Predominantly used in metals (steel, alloys, aluminum). It certifies chemical composition and mechanical properties as tested at the mill.

• COA (Certificate of Analysis): Used across chemicals, plastics, pharma, and food industries. It certifies that a batch meets specific standards or regulatory limits.

In short:

• MTR = Compliance with engineering standards (ASTM, ASME, ISO).

• COA = Compliance with quality and safety standards (FDA, EPA, ISO, GMP).

Star Software’s Differentiated Automation Approach

1. MTR Automation Process Flow (Metals Industry)

Process Steps:

1. Document Capture → MTRs ingested from mills, suppliers, or OEMs (PDFs, scans, structured docs).

2. Data Extraction → Key fields parsed (heat number, grade, chemical composition, tensile, hardness).

3. Standards Matching → Automated mapping against ASTM/ASME standards.

4. Tolerance Validation → Checks for property ranges (e.g., carbon %, tensile strength).

5. Traceability Linking → Heat number linked to specific lots, purchase orders, and downstream products.

6. Compliance Report → Auto-generated compliance certificates for customers/regulators.

2. COA Automation Process Flow (Plastics/Pharma/Chemicals)

Process Steps:

1. Document Capture → COAs received from resin suppliers, labs, or pharma QA.

2. Data Extraction → Specs like melt flow index, density, additives, heavy metals, active ingredient % parsed.

3. Regulatory Mapping → Auto-check against FDA 21 CFR (food contact), GMP guidelines, EPA limits, PFAS bans.

4. Quality Rules Validation → Tolerance checks per SOP (± ranges for viscosity, assay results, microbial limits).

5. Lot-to-Batch Mapping → Batch-level traceability linked to finished goods.

6. Audit-Ready Dashboard → Packaged reports for FDA, EPA, or customer audits.

Chart: Comparing MTR vs. COA Automation

Why Star Software’s Approach Matters

• No one-size-fits-all: A metals manufacturer needs ASTM compliance; a pharma plant needs FDA-ready dossiers. Star Software’s automation adapts to both.

• End-to-end traceability: Heat numbers in metals or batch IDs in pharma—both are linked across ERP/QMS systems.

• Audit readiness: Whether it’s a customer audit in aerospace metals or an FDA inspection in pharma plastics, compliance packs are generated instantly.

• Sustainability edge: In plastics, COA automation supports PFAS bans and recyclability claims; in metals, MTR automation supports ESG-linked steel supply chain audits.

MTRs and COAs may seem like paperwork, but they are the passport of trust in manufacturing. By differentiating how each is automated, Star Software ensures accuracy, compliance, and efficiency across industries—helping U.S. manufacturers build not just stronger products, but also stronger reputations.

U.S. plastics is a heavyweight: $97.7B in GDP (NAICS 326) in 2023 and employs over 716K  people as of July 2025. That scale makes every quality slip, non-compliance, or spec variance expensive—and environmentally costly. Automating Certificates of Analysis (COAs) is no longer back-office hygiene; it’s how resin producers, converters, and brand owners prove compliance, cut waste, and hit sustainability targets. FREDBureau of Labor Statistics

Why COAs Matter So Much in Plastics

• Quality & Safety: COAs verify resin grade, MFI, density, additives, heavy metals, and migration compliance—foundational for FDA 21 CFR Part 177 food-contact applications. Automating intake/validation reduces manual error and speeds release-to-run. eCFRU.S. Food and Drug Administration

• Regulatory Proof: COAs (plus attached test reports) provide the evidence trail for PFAS restrictions in packaging and evolving state EPR laws. In audits, “show me the paper” really means “show me the data.” U.S. Food and Drug AdministrationCalRecycle Home Pageepr.sustainablepackaging.org

The Compliance & Policy Backdrop (U.S.)

• Food-contact plastics: FDA regulates the substances that can contact food (21 CFR 177). COAs confirm the polymer/additive system used is authorized and within limits. eCFRU.S. Food and Drug Administration

• PFAS in packaging: FDA notes that as of Jan 2024 PFAS grease-proofers are no longer being sold into the U.S. market for food contact—brands still need supplier attestations/COAs to enforce this at scale. States are also enacting PFAS bans in packaging. U.S. Food and Drug AdministrationBCLP

• EPR & recyclability (California SB 54): Producers must shift packaging to recyclable/compostable formats and hit 30% recycling by 2028, 65% by 2032, with fees tied to design impact. Accurate COA data (resin, additives, colorants) supports recyclability claims and fee calculations. CalRecycle Home Pageepr.sustainablepackaging.org

• Market pressure: The U.S. Plastics Pact targets: 100% reusable/recyclable/compostable packaging and 30% recycled content by 2025—deadlines many firms are now sliding to 2030, but data demands remain. COAs are the primary, standardized feed for packaging material claims. U.S. Plastics PactThe Wall Street Journal

Sustainability & Pollution Control: Where COA Automation Pays Off

• Less scrap, fewer purges: Automated COA checks (e.g., MFI ± tolerance, ash %, volatiles) before release prevent out-of-spec runs, cutting start-up scrap and purge waste.

• Cleaner inventories: Systematic COA gating keeps restricted additives (e.g., PFAS, certain phthalates) out of BOMs, reducing the risk of off-spec lots entering production and later landfill.

• Easier reporting: The EPA’s Toxics Release Inventory (TRI) increasingly scrutinizes plastics and additives (including PFAS). Digitized COA data streamlines annual disclosures and internal hotspot finding. In 2023, facilities reported managing ~1.56 million lbs of PFAS production-related waste—expect oversight to grow. US EPARegulations.gov

• Circularity claims that stick: With <10% of U.S. plastic waste recycled, brands need defensible resin and recycled-content data to improve real outcomes (and avoid greenwashing). COA automation provides the audit trail for rPCR content and design-for-recycling choices. National Academies

What “Good” COA Automation Looks Like

1. Multi-format capture: Ingest supplier COAs from PDFs/portals/EDI; parse key specs (MFI, density, tensile, Vicat, additive IDs, batch/lot).

2. Rules & tolerance engine: Auto-validate against SOPs: grade-to-SKU mapping, tolerance bands, food-contact applicability (21 CFR section), PFAS-free attestations, colorant restrictions, recycled-content thresholds.

3. Supplier scorecards: Track first-pass acceptance, variance trends, late/missing COAs; trigger CAPAs.

4. Traceability chain: Link each finished lot back to resin lots, additive masterbatches, and their COAs for instant recall readiness.

5. Compliance dashboards: One-click dossiers for FDA food-contact, state PFAS packaging rules, CA SB 54 recyclability/readiness, and TRI support files. eCFRBCLPCalRecycle Home Pageepr.sustainablepackaging.orgUS EPA

Where to Start (Quick Wins by Segment)

• Packaging (food & personal care): Enforce PFAS-free and 21 CFR 177 alignment; capture recycled-content COAs to substantiate label claims and meet retailer requirements. U.S. Food and Drug AdministrationeCFR

• Medical & pharma plastics: Tighten biocompatibility inputs and lot-level test data; keep digitized trails for audits.

• Automotive & durables: Standardize COA checks for thermal/mechanical specs to cut rework; map additives for DfR (design for recycling).

• Resin producers & compounders: Provide machine-readable COAs (JSON/CSV) with batch analytics to reduce downstream NCRs and bolster service levels.

How Star Software Helps

Star Software automates the COA lifecycle for plastics manufacturers and brand owners:

• Intelligent ingestion: Reads multi-vendor COAs (scans, structured PDFs, spreadsheets) and normalizes fields like resin family, MFI, density, tensile, colorant IDs, RoHS/REACH flags.

• Policy checks: Applies your FDA 21 CFR 177 mapping, PFAS-free attestations, and SB 54 recyclability logic to approve/hold lots automatically.

• Traceability graph: Links raw-material COAs to WIP/FG lots for instant backward/forward tracing.

• Audit & reporting: Generates binder-ready compliance packs for customers and regulators; exports data to ERP/QMS/LIMS.

Learn more about our AI-enabled COA automation

In the pharmaceutical industry, precision isn’t just important—it’s non-negotiable. From batch release to regulatory inspections, every stage of production is governed by strict Good Manufacturing Practices (GMP). Among the most critical documents in this process is the Certificate of Analysis (COA)—a quality assurance report that verifies product compliance with safety and quality standards.

Yet, many pharmaceutical companies still rely on manual methods to verify COAs. While this may have sufficed in the past, today’s regulatory environment, digital compliance mandates, and sheer volume of data make manual COA verification a major liability.

Let’s break down why manual COA handling fails GMP standards—and how automation offers a future-ready solution.

❌ The Problem with Manual COA Verification

1. Human Errors and Inconsistencies

COAs are often received in unstructured formats—PDFs, scanned images, or printed documents. Manually reviewing these documents introduces human error, especially when comparing dozens of parameters across lab systems and supplier data. A single oversight could mean a non-compliant batch reaches the market or a compliant one gets rejected.

2. Delayed Batch Release

Manual verification is time-consuming. QA teams often spend hours per COA cross-checking values against product specifications or material master records. This leads to bottlenecks in batch release, impacting downstream production and delivery timelines.

3. Poor Traceability and Auditability

GMP demands clear, timestamped, and traceable documentation for all quality decisions. Paper-based or spreadsheet-driven processes lack audit trails, making it hard to demonstrate compliance during FDA or MHRA inspections.

4. Compliance Risks with 21 CFR Part 11

Manual COA review processes often bypass electronic recordkeeping standards outlined under 21 CFR Part 11, which governs data integrity, authentication, and electronic signatures. Failing to comply could trigger warning letters or product holds.

✅ The Tech-Driven Fix: COA Automation with AI

At Star Software, we’ve reimagined COA verification through intelligent automation—removing manual friction while enhancing accuracy and compliance.

🔹 Intelligent Document Processing (IDP)

Our system uses AI-powered OCR to extract structured data from unstructured COAs—whether it’s a scanned PDF from a supplier or a digitally signed document. No more manual typing or value-by-value matching.

🔹 Auto-Matching with Product Specs

The extracted data is automatically matched with predefined quality specifications from ERP, LIMS, or MDM systems. Any out-of-spec values or missing data are instantly flagged—reducing decision latency.

🔹 Digital Audit Trails and Validation Logs

Every COA processed generates a secure digital trail, complete with validation logic, user activity logs, and time-stamped approvals—ensuring you’re always audit-ready.

🔹 21 CFR Part 11 and GMP-Ready

The platform supports electronic signatures, access control, and tamper-proof records, aligning with global regulatory requirements for data integrity and electronic documentation.

📈 Real Impact: What Pharma Teams Achieve with COA Automation

• Up to 80% reduction in COA processing time

• Zero data transcription errors

• Audit readiness within seconds

• Faster batch release and improved throughput

• Better collaboration across QA, procurement, and compliance

👩‍⚕️ From Risk to Resilience: Future-Proof Your COA Process

As regulators sharpen their focus on data integrity and operational transparency, clinging to manual COA verification is no longer safe—or sustainable. Automation is more than a digital upgrade; it’s a strategic move to align your operations with GMP, accelerate compliance, and safeguard product quality.

Explore how Star Software’s COA Automation platform can future-proof your pharma operations.
Schedule a free demo

The recent slide of the U.S. dollar is stirring waves far beyond the currency markets — and the American metal industry is feeling the ripple effects. While a weaker dollar may benefit exporters by making U.S. goods more competitive abroad, the situation is far more complex. Inflationary pressures, evolving tariff policies, and compliance demands are creating a tightrope walk for manufacturers, traders, and investors.

What the Weakening Dollar Signals

At face value, a depreciating dollar typically boosts U.S. exports by making them more affordable for foreign buyers. This should be a tailwind for American metal producers shipping steel, aluminum, and other raw materials overseas. However, in today’s volatile economic climate, the dollar’s fall is being read as a warning signal.

As Steve Englander of Standard Chartered aptly puts it, “Having a weak dollar or a strong dollar isn’t the issue. The issue is: What is it telling you about how the world sees your policies?”

Initially buoyed by pro-growth sentiment around the Trump administration’s economic policies, the dollar peaked in early 2025. But the optimism was short-lived. Concerns over high interest rates, stubborn inflation, and aggressive tariff rhetoric spooked investors. The result? A slide in confidence toward U.S. assets, including metals.

Metal Sector in Flux: Between Demand and Disruption

For domestic producers, the weakening dollar presents both opportunities and challenges:

• Export Boost: A cheaper dollar could increase global demand for U.S.-made steel and aluminum, especially in emerging markets.

• Costlier Imports: On the flip side, metal manufacturers reliant on imported raw materials or machinery are facing higher input costs.

• Tariff Uncertainty: The looming threat of new tariffs disrupts predictable trade flows, further complicating sourcing and pricing strategies.

What should be a straightforward export advantage is now a delicate balancing act. Tariff threats and global trade instability undermine long-term planning, with buyers and suppliers alike becoming more cautious.

The Hidden Hero: Compliance

Amid these uncertainties, regulatory compliance has emerged as a silent stabilizer for the U.S. metal industry.

Exporters must now double down on transparent documentation — including Material Test Reports (MTRs), Certificates of Origin, and Certificates of Analysis (CoAs) — to meet international trade standards and avoid costly delays or rejections.

Compliance plays three critical roles:

1. Risk Mitigation: In a climate of shifting tariffs and trade scrutiny, compliant documentation helps de-risk international shipments.

2. Trust Building: Global buyers demand traceability and accountability — accurate paperwork earns their confidence.

3. Automation Advantage: Companies that automate compliance workflows are staying leaner and more agile, turning what was once a back-office function into a strategic differentiator.

Conclusion: Strengthening Through Smart Strategy

The weakening dollar, driven by concerns over inflation, tariffs, and investor confidence, is a wake-up call for U.S. manufacturers — especially those in the metals sector. In this uncertain environment, compliance isn’t just a legal obligation — it's a competitive weapon.

By embracing automated documentation systems and staying ahead of regulatory shifts, American metal producers can transform short-term currency volatility into long-term trade resilience.